<p><strong>Pediatric Use</strong>: Safety and efficacy of Semaglutide have not been established in pediatric patients (younger than 18 years).<br />
<br />
<strong>Geriatric Use</strong>: No overall differences in safety or efficacy were detected between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.<br />
<br />
<strong>Renal Impairment</strong>: The safety and efficacy of Semaglutide was evaluated in a 26-week clinical study that included 324 patients with moderate renal impairment (eGFR 30 to 59 mL/min/1.73 m2). In patients with renal impairment including end-stage renal disease (ESRD), no clinically relevant change in semaglutide pharmacokinetics (PK) was observed. No dose adjustment of Semaglutide is recommended for patients with renal impairment.<br />
<br />
<strong>Hepatic Impairment</strong>: In a study in subjects with different degrees of hepatic impairment, no clinically relevant change in semaglutide pharmacokinetics (PK) was observed. No dose adjustment of semaglutide is recommended for patients with hepatic impairment.</p>